Warning: You are using an outdated Browser, Please switch to a more modern browser such as Chrome, Firefox or Microsoft Edge.

Lavish windfall gains from biotechnological unicorns

L

LOW RISK for entreprises

  • Fragmentation

  • Internationalization

  • Capital Intensity

  • Profitability

  • Fragmentation

  • Internationalization

  • Capital Intensity

  • Profitability

Updated in July 2021.
  • Medicine demand bolstered by growing middle classes in Emerging Markets and aging population as a whole
  • Resilience of drug spending irrespective of economic cycle, coupled with huge public support for improving people’s healthcare needs
  • High level of R&D expenditure well covered by strong cash generation amid the pressing need for Covid-19 vaccines to reach herd immunity worldwide
  • mRNA technology close to being a game-changer for the sector, especially in oncology treatments
  • Venture capitalists and public investors’ appetite for investing in (listed) biotechnology firms
  • Supply-chain disruptions due to states’ pressure to ‘reshore’ drug production within Western countries
  • Lengthy procedures for new drug approvals on top of stiff price regulations
  • Generic drug makers plagued with lower profit margins and higher debt gearing than patented drug ones
  • Limited production capacities making it difficult to meet urgent delivery needs of all Covid-19 vaccines worldwide
  • Bargaining power of India and China regarding vaccine production and delivery
Trade credit insurance covers your receivables due within 12 months so that your cash flow is safeguarded.

Our information tracks the financial health of your customers and we update you so that you can trade with confidence.

If your customers become insolvent or fall into protracted default, you will be indemnified for the cost of goods and services you have delivered.

Key players

Country Role Sector risk
China

#1 market by revenue

A

Low risk

United States

#2 market by revenue

B

Medium risk

Switzerland

#3 market by revenue

A

Low risk

India

#4 market by revenue

A

Low risk

Germany

#5 market by revenue

A

Low risk


Let us help you today

Fill in the form below and our trade credit specialists will be in touch as soon as possible.

​ ​
​ ​